Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Shares Outstanding (Diluted Average) (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $92.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.21% to $92.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $92.6 million, a 2.21% increase, with the full-year FY2025 number at $92.6 million, up 2.21% from a year prior.
  • Shares Outstanding (Diluted Average) was $92.6 million for Q4 2025 at Myriad Genetics, down from $93.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $93.1 million in Q3 2025 to a low of $76.0 million in Q1 2021.
  • A 5-year average of $84.4 million and a median of $81.8 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 1.49% in 2023, then increased 10.99% in 2024.
  • Myriad Genetics' Shares Outstanding (Diluted Average) stood at $78.0 million in 2021, then increased by 3.33% to $80.6 million in 2022, then grew by 2.73% to $82.8 million in 2023, then increased by 9.42% to $90.6 million in 2024, then increased by 2.21% to $92.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Shares Outstanding (Diluted Average) are $92.6 million (Q4 2025), $93.1 million (Q3 2025), and $92.0 million (Q2 2025).